Business
TNI BioTech, Inc. Receives Confirmation of Transfer of IND application and Orphan Drug Designation
TNI BioTech, Inc. Receives Confirmation of Transfer of IND application and Orphan Drug Designation.
About this update from Biostax Corp.
[{"type":"text","content":"\n \n 0\n 0\n 1\n 760\n 4334\n Brinen & Associates, LLC\n 36\n 10\n 5084\n 14.0\n \n \n \n \n\n\n\n \n Normal\n 0\n \n \n \n \n false\n false\n false\n \n EN-US\n JA\n X-NONE\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n\n\n\n /* Style Definitions */\ntable.MsoNormalTable\n\t{mso-style-name:\"Table Normal\";\n\tmso-tstyle-rowband-size:0;\n\tmso-tstyle-colband-size:0;\n\tmso-style-noshow:yes;\n\tmso-style-priority:99;\n\tmso-style-parent:\"\";\n\tmso-padding-alt:0in 5.4pt 0in 5.4pt;\n\tmso-para-margin:0in;\n\tmso-para-margin-bottom:.0001pt;\n\tmso-pagination:widow-orphan;\n\tfont-size:12.0pt;\n\tfont-family:\"Times New Roman\";}\n\n\n\n\n\n\n\nTNI BioTech, Inc. Receives Confirmation of Transfer of\nIND application and Orphan Drug Designation\n\n \n\nBETHESDA,\nMaryland-- (Marketwire –May 6, 2013) - TNI BioTech, Inc., (PINKSHEETS: TNIB) has received acknowledgement from the Department of\nHealth and Human Services confirming the Food and Drug Administration’s (FDA)\nreceipt of the change in sponsorship of the investigational new drug\napplication (IND) for Naltrexone HCL and the orphan drug designation for\n[met5]-enkephalin and the orphan drug designation for the use of low dose\nnaltrexone in the treatment of pediatric patients with Crohn’s Disease.\n\n \n\nThe Company signed an agreement for the acquisition of\npatent rights for the intellectual property of Dr. Jill Smith and LDN\nResearch Group, LLC, whose members are Dr. Ian S. Zagon, Dr. Patricia\nJ. McLaughlin and Moshe Rogosnitzky and orphan drug designation by\nthe FDA to a novel late-stage drug, trademarked “LDN,” for the treatment of\nPediatric Crohn’s Disease. The patent covers methods and formulations for\ntreatment of the inflammatory and ulcerative diseases of the bowel, using\nnaltrexone in low doses as an opioid antagonist. Endogenous opioids...